T-Regulatory Cells: Restoring Immune Balance in Neuroinflammatory Disease
Dr. Uladzislau Tsvirko
28 February 2025
In autoimmune neurological conditions, the immune system itself drives tissue destruction. T-regs address this through targeted suppression of pathological immune responses — without the broad immunosuppression that increases infection risk.
The Autoimmune Component
In conditions such as multiple sclerosis, autoimmune encephalitis, and Guillain-Barré syndrome, the patient’s own immune system is a primary driver of neural tissue destruction. Conventional immunosuppressive drugs address this by broadly dampening immune function — an approach that reduces pathological inflammation but simultaneously increases susceptibility to infection and impairs normal immune surveillance. T-regulatory cell therapy represents a fundamentally different strategy: restoring immune homeostasis through targeted suppression of misdirected immune responses while preserving normal protective function.
Biology of T-Regulatory Cells
T-regs are a specialised subset of CD4+ T-lymphocytes defined by the expression of CD25 and the transcription factor FoxP3 (CD4+CD25+FoxP3+). They represent the immune system’s endogenous mechanism for maintaining self-tolerance — the ability to distinguish the body’s own tissue from foreign pathogens. In healthy individuals, T-regs continuously patrol the body, suppressing immune responses directed against self-antigens. In autoimmune neurological disease, this regulatory function is overwhelmed or defective, allowing immune cells to attack myelin, neurons, or neuromuscular junctions.
Suppressive Mechanisms
T-regs suppress immune overactivation through four complementary pathways. First, they secrete inhibitory cytokines — IL-10, IL-35, and TGF-β — that directly dampen effector T-cell activation. Second, they engage in direct cell-contact inhibition via the surface molecule CTLA-4. Third, they metabolically disrupt pro-inflammatory cells by consuming IL-2, a cytokine essential for effector T-cell survival. Fourth, they induce tolerogenic dendritic cells that further propagate immune suppression. In the central nervous system specifically, T-regs cross the blood-brain barrier and reduce neuroinflammation by suppressing microglial activation and limiting the infiltration of pro-inflammatory lymphocytes.
Manufacturing Process
T-regs are isolated from the patient’s peripheral blood using immunomagnetic selection targeting CD4+CD25+ populations. The isolated cells are expanded in culture with anti-CD3/CD28 stimulation and high-dose IL-2 to achieve therapeutic numbers while maintaining FoxP3 expression. Purity is verified by flow cytometry: >85% CD4+CD25+FoxP3+ expression is required before clinical release. The entire process takes 10–14 days and is performed exclusively in BioCells Medical’s certified laboratory.
Clinical Significance
T-reg therapy directly addresses the immune-mediated component of neurological disease. Rather than suppressing the entire immune system — an inherently risky approach that increases vulnerability to opportunistic infection — T-regs selectively suppress the pathological immune responses driving tissue destruction while leaving normal immune surveillance intact. This distinction between targeted immune regulation and broad immunosuppression is clinically significant: it offers the possibility of meaningful immune intervention without the safety compromises inherent in conventional immunosuppressive pharmacotherapy.